TWST Valuation

Twist Bioscience Corp

Add to Watchlist

Advanced Chart

27.630

+1.99(7.761%)1D

Overview
Forecast
Valuation
Earnings

TWST Relative Valuation

TWST's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TWST is overvalued; if below, it's undervalued.

Historical Valuation

Twist Bioscience Corp (TWST) is now in the Undervalued zone, suggesting that its current forward PS ratio of 3.71 is considered Undervalued compared with the five-year average of -18.28. The fair price of Twist Bioscience Corp (TWST) is between 35.90 to 50.00 according to relative valuation methord. Compared to the current price of 27.63 USD , Twist Bioscience Corp is Undervalued By 23.03%.

Relative Value

Fair Zone

35.90-50.00

Current Price：27.63

23.03%

Undervalued

-17.94

Trailing

Forward

-18.95

EV/EBITDA

Twist Bioscience Corp. (TWST) has a current EV/EBITDA of -18.95. The 5-year average EV/EBITDA is -17.98. The thresholds are as follows: Strongly Undervalued below -44.20, Undervalued between -44.20 and -31.09, Fairly Valued between -4.87 and -31.09, Overvalued between -4.87 and 8.24, and Strongly Overvalued above 8.24. The current Forward EV/EBITDA of -18.95 falls within the Historic Trend Line -Fairly Valued range.

-14.26

EV/EBIT

Twist Bioscience Corp. (TWST) has a current EV/EBIT of -14.26. The 5-year average EV/EBIT is -15.94. The thresholds are as follows: Strongly Undervalued below -40.56, Undervalued between -40.56 and -28.25, Fairly Valued between -3.64 and -28.25, Overvalued between -3.64 and 8.67, and Strongly Overvalued above 8.67. The current Forward EV/EBIT of -14.26 falls within the Historic Trend Line -Fairly Valued range.

3.71

Twist Bioscience Corp. (TWST) has a current PS of 3.71. The 5-year average PS is 15.63. The thresholds are as follows: Strongly Undervalued below -15.83, Undervalued between -15.83 and -0.10, Fairly Valued between 31.37 and -0.10, Overvalued between 31.37 and 47.10, and Strongly Overvalued above 47.10. The current Forward PS of 3.71 falls within the Historic Trend Line -Fairly Valued range.

49.13

P/OCF

Twist Bioscience Corp. (TWST) has a current P/OCF of 49.13. The 5-year average P/OCF is 149.83. The thresholds are as follows: Strongly Undervalued below -1555.64, Undervalued between -1555.64 and -702.91, Fairly Valued between 1002.56 and -702.91, Overvalued between 1002.56 and 1855.30, and Strongly Overvalued above 1855.30. The current Forward P/OCF of 49.13 falls within the Historic Trend Line -Fairly Valued range.

147.40

P/FCF

Twist Bioscience Corp. (TWST) has a current P/FCF of 147.40. The 5-year average P/FCF is -24.03. The thresholds are as follows: Strongly Undervalued below -77.64, Undervalued between -77.64 and -50.83, Fairly Valued between 2.77 and -50.83, Overvalued between 2.77 and 29.57, and Strongly Overvalued above 29.57. The current Forward P/FCF of 147.40 falls within the Strongly Overvalued range.

Twist Bioscience Corp (TWST) has a current Price-to-Book (P/B) ratio of 3.42. Compared to its 3-year average P/B ratio of 3.50 , the current P/B ratio is approximately -2.11% higher. Relative to its 5-year average P/B ratio of 5.45, the current P/B ratio is about -37.19% higher. Twist Bioscience Corp (TWST) has a Forward Free Cash Flow (FCF) yield of approximately -4.44%. Compared to its 3-year average FCF yield of -9.65%, the current FCF yield is approximately -53.97% lower. Relative to its 5-year average FCF yield of -7.59% , the current FCF yield is about -41.51% lower.

3.42

P/B

Median3y

3.50

Median5y

5.45

-4.44

FCF Yield

Median3y

-9.65

Median5y

-7.59

Competitors Valuation Multiple

The average P/S ratio for TWST's competitors is 2.56, providing a benchmark for relative valuation. Twist Bioscience Corp Corp (TWST) exhibits a P/S ratio of 3.71, which is 44.74% above the industry average. Given its robust revenue growth of 17.91%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

TWST.O

Twist Bioscience Corp

Cogent Biosciences Inc

Loss

1.53B

DYN.O

Dyne Therapeutics Inc

Loss

1.60B

AUPH.O

Aurinia Pharmaceuticals Inc

Immunocore Holdings PLC

3.84

29.93%

1.61B

Performance Decomposition

Market capitalization of TWST decreased by 36.10% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -11.37 to -18.90.

The secondary factor is the Revenue Growth, contributed 17.91%to the performance.

Overall, the performance of TWST in the past 1 year is driven by P/E Change. Which is more unsustainable.

17.91%

81.46M → 96.06M

Revenue Growth

-120.21%

-105.04 → 21.23

Margin Expansion

66.20%

-11.37 → -18.90

P/E Change

-36.10%